Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Abbott Laboratories | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Abbott Laboratories

Nothing can stop Humira.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Abbott Laboratories 1Q

1Q Revenues: $7.7 billion (+15%)

1Q Earnings: $1.0 billion (-30%)

Comments: Worldwide pharma sales were $4.1 billion (+13%, with 4% of that coming from currency rates). Domestic pharma sales grew 12% to $1.7 billion. Nutritional sales were up 12% to $1.3 billion, diagnostics sales grew 12% to $915 million, and vascular sales were up 16% to $747 million. Pharma sales were driven by Humira, which grew 36% to $1.4 billion, including a 7% bump from currency rates. 1Q09 earnings were boosted by the favorable impact of a contingent liability; without it, earnings would have been flat in 1Q10.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters